Dawnrays Pharmaceutical Holdings Ltd. stock analysis
Want to see HK:2348 full AI Analyst Report?
Debt-to-equity of about 0.02 and equity of roughly 3.39bn against 4.01bn of assets indicate conservative financing. This provides a substantial cushion against stress and preserves flexibility to fund operations, investment, or shareholder returns.
Gross margin near 49%, net margin around 17%, and EBIT/EBITDA margins near 19%/26% show that the portfolio currently produces meaningful profitability. Such margins can support reinvestment and provide resilience if operating conditions soften.
Operating cash flow of 355m and free cash flow of 236m in 2025 represent a material recovery and show that the business can generate internal funding. Positive cash generation supports working capital, product investment, and financial flexibility over coming quarters.
The sharp decline in net income from 565m to 208m in 2025, despite 7.7% revenue growth, points to unstable earnings conversion. If this pattern persists, it could reduce reinvestment capacity and make future profitability less predictable.
Revenue declined during 2023–2024 before recovering in 2025, indicating an uneven top-line trajectory rather than a consistently expanding base. This inconsistency can make capacity planning, commercial investment, and sustainable earnings growth harder to manage.
Free cash flow was only 45m in 2024 versus 236m in 2025, while cash-flow coverage of net income has often been below 1x. This variability means reported profits do not reliably translate into usable cash each year, limiting planning confidence.
The latest announcement is out from Dawnrays Pharmaceutical Holdings Ltd. ( ($HK:2348) ). Dawnrays Pharmaceutical (Holdings) Limited reported unaudited interim results for the six months ended 30 June 2026 that
Dawnrays Pharmaceutical Holdings Ltd. ( ($HK:2348) ) has shared an announcement. Dawnrays Pharmaceutical’s wholly owned unit Suzhou Dawnrays has agreed to form a biopharmaceutical venture capital investment fund partnership with
Dawnrays Pharmaceutical Holdings Ltd. ( ($HK:2348) ) has shared an update. Dawnrays Pharmaceutical’s subsidiary Suzhou Dawnrays Pharmaceutical Co., Ltd. has secured Chinese regulatory approval to produce and market Trelagliptin Succinate
Dawnrays Pharmaceutical Holdings Ltd. ( ($HK:2348) ) has provided an announcement. Dawnrays Pharmaceutical (Holdings) Limited has called its Annual General Meeting for 22 May 2026 in Hong Kong, where shareholders
Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets. Its operations are divided into two main divisions: Intermediates and Bulk Medicines, and Finished Drugs. The company's diverse product portfolio features a range of antibiotics, including pharmaceutical intermediates, bulk active ingredients, powdered formulations for injection, and oral antibiotic preparations. Furthermore, Dawnrays offers specialized medications addressing various bodily systems and conditions, such as those for cardiovascular health, allergies, Hepatitis B Virus (HBV), digestive and urinary issues, antipyretic-analgesic (fever and pain relief), respiratory ailments, and endocrine disorders. These system-specific drugs are dispensed in familiar forms like tablets, capsules, and granules. Founded in 1995, the firm maintains its headquarters in Wan Chai, Hong Kong, and is a subsidiary of Fortune United Group Limited.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |
